How Flatiron Supported The Beat AML® Master Clinical Trial

The Beat AML® Master Clinical Trial, initiated by the Leukemia and Lymphoma Society (LLS) in 2016, represents a groundbreaking approach to precision medicine for Acute Myeloid Leukemia (AML). By employing advanced genomic technology, the trial identifies genetic mutations in patients' cancers and aligns them with targeted therapies. Distinct from conventional trials, Beat AML evaluates multiple treatments concurrently. The trial spans over 20 sites and involves a diverse array of sponsors and technology vendors. To address the trial's intricate data demands, LLS collaborated with Flatiron Health, which supplied EHR-to-EDC technology to enhance data management. This partnership significantly improved data quality, minimized manual errors, and reduced the need for extensive data verification. Consequently, the trial timelines were accelerated, optimizing both time and resources for research sites and sponsors.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Hydrocarbon Online? Subscribe today.